Ignite Creation Date:
2024-05-06 @ 3:52 PM
Last Modification Date:
2024-10-26 @ 1:59 PM
Study NCT ID:
NCT04789434
Status:
UNKNOWN
Last Update Posted:
2021-11-22
First Post:
2021-03-06
Brief Title:
PD-1 Inhibitor Tislelizumab Maintenance Therapy in Newly Diagnosed DLBCL Patients After ASCT
Sponsor:
Ruijin Hospital
Organization:
Ruijin Hospital
Study Overview
Official Title:
PD-1 Inhibitor Tislelizumab Maintenance Therapy in Newly Diagnosed DLBCL Patients After ASCT A Multicenter Randomized Controlled Clinical Study on Efficacy and Safety
Status:
UNKNOWN
Status Verified Date:
2021-11
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a multicenter randomized controlled prospective clinical trial The objective is to investigate the efficacy and safety of Tislelizumab maintenance therapy in newly diagnosed diffuse large B-cell lymphoma DLBCL patients after autologous hematopoietic stem cell transplantation ASCT
Detailed Description:
This is a multicenter randomized controlled prospective clinical trial The objective is to investigate the efficacy and safety of Tislelizumab maintenance therapy in newly diagnosed diffuse large B-cell lymphoma DLBCL patients after autologous hematopoietic stem cell transplantation ASCT 94 patients were randomly divided into two groups according to the ratio of 11 The whole trial included screening period day-28 to day-1 treatment period Tislelizumab 200mg every 8 weeks 12 times and follow-up period 2 years after the enrollment
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None